• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

Heat Stable Carbetocin: A Heat-Stable Alternative to Oxytocin?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Oxytocin is the first line drug for prevention of PPH but due to the necessity for cold-storage, it is not always a viable option in many parts of the world
  • Heat-stable carbetocin is an oxytocin analogue
    • Maintains stability with ≥95% peptide purity over 36 months, even at 30°C and 75% relative humidity
      • 6 months at 40°C
      • 3 months at 50°C
    • Optimum pH  5.45 (5.25–5.65)
    • Not sensitive to freezing or light
  • Widmer et al. (NEJM 2018) compared the efficacy of heat-stable carbetocin to oxytocin for PPH prevention

METHODS:

  • Randomized, double-blind, controlled non-inferiority trial
    • 23 hospital sites in 10 countries (2015-2018)
    • Vaginal deliveries
  • Patients were randomized to the following study arms
    • Heat-stable carbetocin 100 µg IM
    • Oxytocin 10 IU IM
  • Postpartum blood loss calculated as follows
    • Blood collected in plastic drape
    • Blood collected for 1 hour or for 2 hours if bleeding continued
    • Drape (including the blood) was weighed (grams) converted to volume (mm) after weight of drape subtracted
  • Primary outcomes
    • Composite outcome of (1) proportion of women with blood loss of at least 500 ml; (2) Use of additional uterotonic agents at 1 hr and up to 2 hrs
    • Proportion of women with blood loss of at least 1000 ml
  • Secondary outcomes
    • Other measurements related to blood loss (e.g., additional medications/interventions)
    • Adverse effects

RESULTS:

  • 29,645 women underwent randomization
  • Primary outcome #1: The frequency of blood loss of at least 500 ml or the use of additional uterotonic agents
    • 14.5% in the carbetocin group vs 14.4% in the oxytocin group
    • Consistent with non-inferiority of carbetocin
  • Primary outcome #2: The frequency of blood loss of at least 1000 ml
    • 1.51% in the carbetocin group vs 1.45% in the oxytocin group
    • Close to showing non-inferiority of carbetocin but may have been underpowered (upper 95% confidence limit exceeded the noninferiority margin)
      • Researchers planned on 2% 1000 ml blood loss but in the study, 1000 ml blood loss was approximately 1.5%
    • The use of additional uterotonic agents, interventions to stop bleeding, and adverse effects did not differ significantly between groups

CONCLUSION:

  • Heat-stable carbetocin performed similarly to oxytocin in preventing blood loss of at least 500 ml or use of other uterotonic agents
  • Noninferiority was not shown for the outcome of blood loss of at least 1000 ml (study was not sufficiently powered for this outcome)
  • The authors state “These data inform care of women in parts of the world where a lack of heat stability is a barrier to the effective prevention of postpartum hemorrhage.”

Learn More – Primary Sources:

Heat-stable Carbetocin versus Oxytocin to Prevent Hemorrhage after Vaginal Birth

Development and stability of a heat‐stable formulation of carbetocin for the prevention of postpartum haemorrhage for use in low and middle‐income countries

image_pdfFavoriteLoadingFavorite

< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Latest Cochrane Review: What is the Most Effective Prophylactic Treatment for Postpartum Hemorrhage?
Postpartum Hemorrhage – Medications to Treat Uterine Atony 

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site